Clinical Trial Update: A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) [Phase 2]

View source ↗

Summary

A 24-month Phase 2a open-label randomized study evaluated Avastin, Lucentis, or Eylea in combination with Fovista for age-related macular degeneration; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• EYLEA (Aflibercept)
• Fovista (E10030)
• Lucentis (ranibizumab)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2019-03-05